Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: FACS-Proteomics strategy toward extracellular vesicles single-phenotype characterization in biological fluids: exploring the role of leukocyte-derived EVs in multiple sclerosis

Fig. 4

Characterization of Leukocytes-derived EVs from healthy controls biofluids. A NTA tracking of size (diameter/nm) and concentration (particles/mL) of pure total EVs population sorted from PB (left) and tears (right). EVs derived from total PB or total tear showed a median diameter of 120.3 nm and 105.4 nm, respectively, falling within the size range detected by AFM reported in the figure. The height cross sectional profiles of representative vesicles of total PB (blue arrow) and total tear (red arrow) are also reported. B NTA tracking of size (diameter/nm) and concentration (particles/mL) of pure Leuko EVs sorted from PB (left) and tears (right). Leuko EVs derived from PB or tears showed a median diameter of 127.5 nm and 145.8 nm respectively, falling within the size range detected by AFM indicated in the figure. The height cross sectional profiles of representative Leuko EVs of PB samples (green arrow) and tears (orange arrow) are also reported

Back to article page